ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014

An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.

Michael S Gordon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.